Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2003-06-25
2009-10-13
Duffy, Patricia A (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S164100, C530S387100, C530S387900, C530S388100, C530S388150, C530S388400, C530S389100, C530S389500, C530S391300
Reexamination Certificate
active
07601351
ABSTRACT:
The present invention relates to antibodies and related molecules that specifically bind to protective antigen ofBacillus anthracis(PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The invention also relates to nucleic acid molecules encoding anti-PA antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
REFERENCES:
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5604201 (1997-02-01), Thomas et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 5840312 (1998-11-01), Mock et al.
patent: 6180356 (2001-01-01), London et al.
patent: 6224870 (2001-05-01), Segal
patent: 6267966 (2001-07-01), Baillie
patent: 6316006 (2001-11-01), Worsham et al.
patent: 6329156 (2001-12-01), Cirino et al.
patent: 6348450 (2002-02-01), Tang et al.
patent: 6387665 (2002-05-01), Ivins et al.
patent: 6770479 (2004-08-01), Lee et al.
patent: 6913756 (2005-07-01), Kearney
patent: 6916474 (2005-07-01), Harvey et al.
patent: 6979449 (2005-12-01), Mock
patent: 2001/0031264 (2001-10-01), Segal
patent: 2002/0034512 (2002-03-01), Ivins et al.
patent: 2002/0039588 (2002-04-01), Collier, Jr. et al.
patent: 2002/0048590 (2002-04-01), Klimpel et al.
patent: 2002/0051791 (2002-05-01), Galloway et al.
patent: 2002/0082386 (2002-06-01), Mangold et al.
patent: 2002/0120106 (2002-08-01), Bogoch et al.
patent: 2002/0142002 (2002-10-01), Galloway et al.
patent: 2002/0197272 (2002-12-01), Galloway et al.
patent: 2003/0003109 (2003-01-01), Galloway et al.
patent: 2003/0059937 (2003-03-01), Ruben et al.
patent: 2003/0118591 (2003-06-01), Levy
patent: 2003/0198595 (2003-10-01), Goldenberg et al.
patent: 2003/0235594 (2003-12-01), Humphreys et al.
patent: 2004/0009178 (2004-01-01), Bowdish et al.
patent: 2004/0009182 (2004-01-01), Myers et al.
patent: 2004/0014707 (2004-01-01), Cirino et al.
patent: 2004/0028695 (2004-02-01), Park et al.
patent: 2004/0058881 (2004-03-01), Humphreys et al.
patent: 2004/0166120 (2004-08-01), Thomas et al.
patent: 2004/0170967 (2004-09-01), Lee et al.
patent: 2004/0171121 (2004-09-01), Leppla et al.
patent: 2004/0235136 (2004-11-01), Singh et al.
patent: 2004/0258699 (2004-12-01), Bowdish et al.
patent: 2005/0106647 (2005-05-01), Harvey et al.
patent: 2005/0123900 (2005-06-01), Dimitrov et al.
patent: 2005/0136049 (2005-06-01), Ledbetter et al.
patent: 2005/0267294 (2005-12-01), Harvey et al.
patent: 2005/0281830 (2005-12-01), Morrow et al.
patent: 2005/0287149 (2005-12-01), Keler et al.
patent: 2006/0002947 (2006-01-01), Humphreys et al.
patent: 2006/0121045 (2006-06-01), Iverson et al.
patent: 0 934 953 (1999-08-01), None
patent: 1 382 615 (2004-01-01), None
patent: 2 400 851 (2004-10-01), None
patent: WO94/18332 (1994-08-01), None
patent: WO99/57266 (1999-11-01), None
patent: WO00/02522 (2000-01-01), None
patent: WO01/45639 (2001-06-01), None
patent: WO01/58956 (2001-08-01), None
patent: WO01/82788 (2001-11-01), None
patent: WO02/04646 (2002-01-01), None
patent: WO02/096467 (2002-12-01), None
patent: WO03/010316 (2003-02-01), None
patent: WO03/087129 (2003-10-01), None
patent: WO03/087378 (2003-10-01), None
patent: WO2004/002415 (2004-01-01), None
patent: WO2004/003139 (2004-01-01), None
patent: WO2004/024067 (2004-03-01), None
patent: WO2004/037861 (2004-05-01), None
patent: WO2004/056874 (2004-07-01), None
patent: WO2004/072117 (2004-08-01), None
patent: WO2004/113522 (2004-12-01), None
patent: WO2005/000884 (2005-01-01), None
patent: WO2005/004791 (2005-01-01), None
patent: WO2005/007804 (2005-01-01), None
patent: WO2005/034841 (2005-04-01), None
Bending (Methods: A Companion to Methods in Enzymology 1995; 8:83-93).
“Anthrax,” Internet publication by National Organization of Rare DIsorders (NORD), 2001.
“Anthrax: Current, comprehensive Information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis,” published by Center for Infectious Disease Research & Policy (CIDRAP) Academic Health Center—University of Minnesota (Jul. 23, 2003).
“Anthrax”, Chapter 19 ofEpidemiology&Prevention of Vaccine-Preventable Diseases, Centers for Disease Control and Prevention, 7thed., Washington, DC: Public Health Foundation, 2002.
“Summary of Notifiable Diseases—United States, 2001,” InMorbidity&Mortality Weekly Report, published by Centers for Disease Control & Prevention, 50(53):1-108 (May 2, 2003) (selected pages).
“Suspected Cutaneous Anthrax in a Laboratory Worker—Texas, 2002,” inMorbidity&Mortality Weekly Report, published by Centers for Disease Control & Prevention, 51(13):279-281(Apr. 5, 2002).
“The Anthrax Vaccine: Is It Safe? Does It Work?,” Joellenbeck et al., eds., Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-Up Agency, Institute of Medicine, National Academy Press, Washington, D.C. (Mar. 2002) (4 pp).
“Update: Investigation of Bioterrorism-Related Anthrax and Interim Guidelines for Clinical Evaluation of Persons with Possible Anthrax,” InMorbidity&Mortality Weekly Report, published by Centers for Disease Control & Prevention, 50(43):941-948 (Nov. 2, 2001).
Abramova et al., “Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979,”Proc. Natl. Acad. Sci. USA, 90:2291-2294 (Mar. 1993).
Anthrax Fact Sheet. Internet publication by Office of Communications & Public Liaison, National Institute of Allergy and Infectious Diseases (May 2002).
Athamna et al., “In vitro susceptibility ofBacillus anthracisto various antibacterial agents and their time-kill activity,”J. Antimicrobiol. Chemother., 53:247-251 (2004).
Barakat et al., “ Fatal Inhalational Anthrax in a 94-Year-Old Connecticut Woman,”JAMA, 287:863-868 (Feb. 20, 2002) (reprinted).
Barnard, et al., “Vaccination against Anthrax with Attenuated Recombinant Strains ofBacillus anthracisThat Produce Protective Antigen,”Infect. Immun., 67:562-567 (Feb. 1999).
Beauregard et al., “Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes Its internalization,”Cell. Microbiol., 2:251-258 (2000).
BioPort, Inc., Anthrax Vaccine Adsorbed (Biothrax™) Product Insert (Jan. 31, 2002).
Bohannon, John, “From Bioweapons Backwater to Main Attraction,”Science, 300:414-415 (Apr. 18, 2003).
Bradley et al., “Identification of the cellular receptor for anthrax toxin,”Nature, 414:225-229 (Nov. 8, 2001).
Bregenholt, S. and J. Haurum, “Pathogen-specific recombinant human polyclonal antibodies: biodefence applications,”Expert Opin. Biol. Ther., 4:387-396 (2004).
Brook et al., “In vitro resistance ofBacillus anthracisSterne to doxycycline, macrolides and quinolones,”Int. J. Antimicrob. Agents, 18:559-562 (2001).
Brossier et al., “Role of Toxin Functional Domains in Anthrax Pathogenesis,”Infect Immun., 68:1781-1786 (Apr. 2000).
Brossier et al., “Anthrax Spores Make and Essential Contribution to Vaccine Efficacy,”Infect. Immun., 70:661-664 (Feb. 2002).
Casadevall, A., “Antibodies for defense against biological attack,”Nature Biotech., 20:114 (Feb. 2002).
Casadevall, A., “Passive Antibody Administration (Immediate Immunity) as a Specific Defense against Biological Weapons,”Emerg. Infect. Dis., 8:833-841 (Aug. 2002).
Casbohm et al., “Flow cytometric analysis of protective antigen-stimulated T cell cytokine production and proliferation in rhesus macaques challenged with aerosolizedBacillus anthracisspores,” presented at Proceedings of the 45th Annual Meeting and ToxExpo, Society of Toxicology (SOT), San Diego, CA, Mar. 5-9, 2006 (poster).
Chang et al., Endemic, Notifiable Bioterrorism-Related Diseases, Unitied States, 1992-1999,Emerg. Infect. Dis., 9:556-564 (May 2003).
Chaudry et al., Quickening the pace of anthrax research: three advances point towards possible therapies,Trends
Gentz Reiner L.
Laird Michael W.
Rosen Craig A.
Duffy Patricia A
Human Genome Sciences Inc.
LandOfFree
Antibodies against protective antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against protective antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against protective antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4056687